However, many issues regarding the use of pathway inhibitors, as well as the most effective drug to use in clinical practice, up to what cancer subtype might benefit the most from PI3K/Akt inhibitors, also due to the side effects, remain to be unsolved. This evidence concerns the gene PIK3CA and cancer.